Abstract
Pregabalin is an anticonvulsant drug that binds to the α2δ (alpha2delta) subunit of the voltage-dependent calcium channel in central nervous system (CNS). Pregabalin decreases the release of neurotransmitters, including glutamate, norepinephrine, substance P and calcitonin gene-related peptide. Purpose of this paper is to offer a qualitative overview of the studies currently available in literature about this drug, examining the effectiveness of pregabalin in its various fields of application. Our analysis, conducted on a final selection of 349 scientific papers, shows that pregabalin may help to reduce pain in diabetic neuropathy, in post-herpetic neuralgia and in some patients affected by fibromyalgia. It is also effective for the treatment of diverse types of seizures and has similar efficacy to benzodiazepines and venlafaxine in anxiety disorder. Moreover, pregabalin may be a therapeutic agent for the treatment of alcohol abuse, in both withdrawal phase and relapse prevention. Possible implications in the treatment of benzodiazepines dependence are emerging, but a potential abuse or misuse of the drug has also been reported. Range of dosage may fluctuate considerably, from 75 mg to 600 mg per day. Further studies are needed to completely understand pregabalin mechanism of action in the different diseases.
Keywords: Abuse, alcohol, anxiety, benzodiazepines, epilepsy, fibromyalgia, neuropathic pain, pregabalin.
Current Pharmaceutical Design
Title:The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview
Volume: 19 Issue: 35
Author(s): Giovanni Martinotti, Matteo Lupi, Fabiola Sarchione, Rita Santacroce, Anatolia Salone, Domenico De Berardis, Nicola Serroni, Marilde Cavuto, Maria Signorelli, Eugenio Aguglia, Alessandro Valchera, Felice Iasevoli and Massimo Di Giannantonio
Affiliation:
Keywords: Abuse, alcohol, anxiety, benzodiazepines, epilepsy, fibromyalgia, neuropathic pain, pregabalin.
Abstract: Pregabalin is an anticonvulsant drug that binds to the α2δ (alpha2delta) subunit of the voltage-dependent calcium channel in central nervous system (CNS). Pregabalin decreases the release of neurotransmitters, including glutamate, norepinephrine, substance P and calcitonin gene-related peptide. Purpose of this paper is to offer a qualitative overview of the studies currently available in literature about this drug, examining the effectiveness of pregabalin in its various fields of application. Our analysis, conducted on a final selection of 349 scientific papers, shows that pregabalin may help to reduce pain in diabetic neuropathy, in post-herpetic neuralgia and in some patients affected by fibromyalgia. It is also effective for the treatment of diverse types of seizures and has similar efficacy to benzodiazepines and venlafaxine in anxiety disorder. Moreover, pregabalin may be a therapeutic agent for the treatment of alcohol abuse, in both withdrawal phase and relapse prevention. Possible implications in the treatment of benzodiazepines dependence are emerging, but a potential abuse or misuse of the drug has also been reported. Range of dosage may fluctuate considerably, from 75 mg to 600 mg per day. Further studies are needed to completely understand pregabalin mechanism of action in the different diseases.
Export Options
About this article
Cite this article as:
Martinotti Giovanni, Lupi Matteo, Sarchione Fabiola, Santacroce Rita, Salone Anatolia, Berardis De Domenico, Serroni Nicola, Cavuto Marilde, Signorelli Maria, Aguglia Eugenio, Valchera Alessandro, Iasevoli Felice and Giannantonio Di Massimo, The Potential of Pregabalin in Neurology, Psychiatry and Addiction: A Qualitative Overview, Current Pharmaceutical Design 2013; 19 (35) . https://dx.doi.org/10.2174/13816128113199990425
DOI https://dx.doi.org/10.2174/13816128113199990425 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Marine Food Protection in Testicular Damages Caused by Diabetes Mellitus
Current Diabetes Reviews Age-Dependent Changes of the temporal Order - Causes and Treatment
Current Aging Science TRPV1 Antagonists as a Potential Treatment for Hyperalgesia
Recent Patents on CNS Drug Discovery (Discontinued) Editorial [Hot Topic: Vascular Complications of Diabetes (Executive Editor: Olga I. Stenina)]
Current Pharmaceutical Design Hip but Not Thigh Intramuscular Adipose Tissue is Associated with Poor Balance and Increased Temporal Gait Variability in Older Adults
Current Aging Science Prevalence of Complications Associated with Diabetes among Pakistani Patients: A Questionnaire-based Survey
Current Diabetes Reviews Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design Antiepileptics and the Treatment of Neuropathic Pain: Evidence from Animal Models
Current Pharmaceutical Design Tricyclic Antidepressants-loaded Biodegradable PLGA Nanoparticles: In Vitro Characterization and In Vivo Analgesic and Anti-Allodynic Effect
Current Nanoscience Optimization of Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management
Current Diabetes Reviews Targeted Therapy of Multiple Myeloma: The Changing Paradigm at the Beginning of the New Millennium
Current Cancer Drug Targets Cultured Adult Animal Neurons and Schwann Cells Give Us New Insights into Diabetic Neuropathy
Current Diabetes Reviews Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Impact on the Development of Diabetic Late Complications
Current Diabetes Reviews Highly Active Antiretroviral Therapy-Induced Liver Injury
Current Drug Safety Glycogen Phosphorylase Inhibitors
Mini-Reviews in Medicinal Chemistry Factors Driving the Choice of the Best Second-Line Treatment of Advanced NSCLC
Reviews on Recent Clinical Trials A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Current Alzheimer Research ADP-Ribosyl Cyclase as a Therapeutic Target for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry